An experimental obesity injection that targets three hormone receptors instead of one has produced average weight loss above 28 percent in a late-stage trial, a figure previously associated with bariatric surgery rather than medication.
Retatrutide, developed by Eli Lilly, is not approved and cannot be prescribed. The company has said it plans to submit a Biologics License Application to the Food and Drug Administration in the first quarter of 2027, which means the earliest realistic availability is later that year and could be well beyond it.
